Introduction
Measurement of lung function is central to the monitoring of cystic fibrosis (CF) lung disease and is used routinely as soon as children are able to reliably reproduce forced respiratory manoeuvres. Falling or persistently poor lung function indices are of concern and trigger further investigations to discover the cause as well as escalations in treatment. We describe a previously unreported cause of persistently poor spirometry in CF and highlight important considerations in the differential diagnosis of children with reduced lung function.
Case report
An 8-year-old girl was transferred to our CF centre 1.5 years previously. She had been diagnosed with CF following meconium ileus requiring laparotomy on day 2 of life. Genetic testing confirmed Delta F508/1078deIT mutations.
At initial assessment it was noted that she had a reproducible, markedly restrictive pulmonary function defect despite training and the use of incentivized spirometry. Forced expiratory volume in 1 second (FEV 1 ) was 0.41 litres (z score -4.7, 35% of predicted) and forced vital capacity (FVC) was 0.54 litres (z scores -4.7, 40% of predicted) with a normal FEV 1 /FVC ratio 0.76 (normal >0.7). This was initially attributed to difficulties in getting a good seal around the mouthpiece but persisted after improvements in technique. Exercise tolerance was reportedly poor but there was little in the way of coughing and she was unable to expectorate sputum. Her chest radiograph showed bilateral peribronchial thickening and some mottled shadowing bilaterally, giving a Chrispin Norman score of 7 (max 38). There was a history of previous infection with Staphylococcus aureus and Pseudomonas aeruginosa had been isolated once, six years previously, but not since then. Treatment with IV antibiotics and optimization of nutrition had only modest effects on spirometric indices, FEV 1 was 0.52 litres (z score -4.1, 44% predicted) and FVC was 0.67 litres (z score -4.0, 49% predicted). Annual liver function tests identified that her alanine aminotransferase (ALT) was raised at 165 iu/L (normal range 7-35 iu/L). Reviewing her annual blood tests, performed at her previous CF centre, it was noted that her aspartate transaminase levels had been consistently elevated (between 150-250 iu/L, normal <70 iu/L) despite normal gamma glutamyl transferase (GGT) and alkaline phosphatase levels and treatment with ursodeoxycholic acid. The liver ultrasound appearances were within normal limits with no evidence of CF-related liver disease.
In the family history we noted that our patient's brother had been diagnosed with Duchenne muscular dystrophy (DMD) three years previously. Hand-grip strength was measured in our patient and found to be significantly reduced at 54 Newtons (N) compared to 102 N, our locally derived predicted value for age-matched non-CF girls (Figure 1 ).
These findings led us to consider that reduced pulmonary function, in spite of relatively good chest radiograph appearances, might be primarily related to muscle weakness rather than CF-related lung damage. Creatine kinase levels were measured and found to be significantly elevated at 5449 iu/L (normal <145 iu/L). Subsequent DNA analysis confirmed that she was heterozygous for the same deletion of the dystrophin gene as her brother. These tests confirmed that our patient is a manifesting carrier of a mutation for DMD.
Discussion
Over 7000 people have CF in the UK and it is the most common autosomal recessive disorder in Caucasians, affecting approximately 1 in 2000 to 1 in 2500 depending on geographical location. 1 DMD has an X-linked genetic inheritance pattern and is caused by an Xp21 mutation which limits production of dystrophin, an essential protein for striated muscle function. 2 It is estimated that over 8000 people have DMD in the UK and it is the most common neuromuscular disorder in children, affecting approximately 1 in 3500 boys worldwide. 3 It is estimated that there are similar numbers of female carriers of DMD mutations as affected male DMD patients. This equates to 1 in 7000 of the overall population (i.e. boys and girls). Of these, approximately 10% are manifesting carriers, varying between 3-22% in reported studies. 4, 5 The estimated risk of having this combination of conditions must, therefore, be less than 1 in 60,000,000. However, there are many other neuromuscular disorders that occur during childhood and that might result in a similar presentation.
Symptomatic female DMD carriers typically present with muscle cramps on exertion and poor exercise tolerance. 4 On occasions there can be severe muscle weakness. While age of onset is variable, weakness before 15 years of age more commonly leads to severe involvement. 6 CK testing is the most reliable method for carrier detection but is only elevated in two-thirds of cases and the results can be difficult to interpret in ethnic and racial groups with normally elevated CK levels. 7 If, as in our case, an affected male relative has a known deletion or duplication of the dystrophin gene, accurate testing for carrier status can be performed.
In our centre we measure hand-grip strength in our CF population, as a research tool to explore its value as a surrogate marker of overall wellbeing. Previous studies in an adult CF population have demonstrated that grip strength correlates closely with sustained maximal inspiratory pressure (r=0.8, p<0.001). 8 This is probably as a result of the association between worsening lung disease and poor nutritional outcomes and the overall effects of the CF disease process on muscle function. Our patient was well-nourished with an above average BMI and so nutritional factors were not thought to be a cause of reduced muscle strength in her case. Interestingly, there is evidence for abnormal CF transmembrane conductance regulator expression in muscle in CF patients as a further cause of reduced muscle strength. This is likely to exacerbate weakness occurring from any other cause. 9 In patients with DMD the decline of lung function is closely related to inspiratory muscle weakness causing a restrictive spirometry picture. 10 We wonder whether there is a synergistic effect of increased muscle weakness from this combination of conditions leading to our patient's significantly abnormal lung function at such a young age.
Our patient's treatment regimen has been modified as a result of the diagnosis of muscle weakness. Airway clearance is achieved using positive pressure via a positive expiratory pressure (PEP) mask. For exacerbations bi-level inspiratory positive airway pressure (BIPAP) is now used to increase ventilation and aid airway clearance. Cough augmentation therapy with a device such as a CoughAssist (Respironics Corp, Millersville, PA, USA) might be considered in the future. Inspiratory muscle training devices have mixed results for both CF and neuromuscular disorders and we have not embarked on their use in this case. Including an exercise routine during inpatient
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stays may no longer be appropriate as muscle fatigue needs to be minimized during a respiratory exacerbation. She is likely to develop a requirement for non-invasive ventilation, particularly overnight, and we will monitor this by history of sleep-disordered breathing and routine overnight pulse oximetry with continuous carbon dioxide monitoring.
Our patient's elevated ALT with a normal GGT result is almost certainly reflective of increased muscle turnover and inflammation rather than CFrelated liver disease. We have, therefore, discontinued ursodeoxycholic acid and there has been no change in specific liver function indices.
Staging of disease progression will be problematic given the unreliability of spirometry. The future availability of non-effort dependent objective indices of lung function, such as the lung clearance index, would be particularly useful in this case. 11 In the absence of the routine availability of such measurements, we believe that the riskbenefits for follow-up thin slice CT-scanning, as a sensitive and accurate imaging modality for delineating the extent and severity of bronchiectasis, is justified in this case. Routine cardiac follow-up for echocardiography and ECG monitoring has also been arranged to screen for the known risk for cardiomyopathy. 12 While the combination of manifesting carriage of a DMD mutation and CF is a very rare association, this case highlights important issues about the assessment of CF patients. There are limitations in the use of spirometry as a measure of CF lung disease, particularly, in situations where muscle weakness can also be a problem. The use of other testing and imaging studies might be of greater value when assessing and deciding on appropriate treatment regimens in such cases.
